Ceftaroline Fosamil: A Review of its Use in the Treatment of Complicated Skin and Soft Tissue Infections and Community-Acquired Pneumonia

Evaluation of the Effect of a Supratherapeutic Dose of Intravenous Ceftaroline Fosamil on the Corrected QT Interval

(2013) Todd A. Riccobene et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Assessment of ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia due to Streptococcus pneumoniae: insights from two randomized trials

(2013) Andrew F. Shorr et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Antimicrobial activity of ceftaroline and comparator agents tested against bacterial isolates causing skin and soft tissue infections and community-acquired respiratory tract infections isolated from the Asia-Pacific region and South Africa (2010)

(2013) Helio S. Sader et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Spectrum and potency of ceftaroline tested against leading pathogens causing skin and soft-tissue infections in Europe (2010)

(2013) David J. Farrell et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

CANVAS 1 and 2: Analysis of Clinical Response at Day 3 in Two Phase 3 Trials of Ceftaroline Fosamil versus Vancomycin plus Aztreonam in Treatment of Acute Bacterial Skin and Skin Structure Infections

(2012) H. David Friedland et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Efficacy of Human Simulated Exposures of Ceftaroline against Phenotypically Diverse Enterobacteriaceae Isolates

(2012) Seth T. Housman et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VitroActivity of Ceftaroline against Clinical Isolates of Streptococcus pneumoniae Recovered in 43 U.S. Medical Centers during 2010-2011

(2012) Gary V. Doern et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Activity of Ceftaroline-Avibactam Tested against Gram-Negative Organism Populations, including Strains Expressing One or More β-Lactamases and Methicillin-Resistant Staphylococcus aureus Carrying Various Staphylococcal Cassette ChromosomemecTypes

(2012) Mariana Castanheira et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Efficacy of Ceftaroline Fosamil in a Staphylococcal Murine Pneumonia Model

(2012) Amira A. Bhalodi et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Evaluation of Ceftaroline Activity versus Ceftriaxone against Clinical Isolates of Streptococcus pneumoniae with Various Susceptibilities to Cephalosporins in anIn VitroPharmacokinetic/Pharmacodynamic Model

(2012) Molly E. Steed et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Summary of Ceftaroline Activity against Pathogens in the United States, 2010: Report from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) Surveillance Program

(2012) Robert K. Flamm et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

AWARE Ceftaroline Surveillance Program (2008–2010): Trends in Resistance Patterns Among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States

(2012) Michael A. Pfaller et al.   CLINICAL INFECTIOUS DISEASES

Prevalence of Methicillin-Resistant Staphylococcus aureus as an Etiology of Community-Acquired Pneumonia

(2012) G. J. Moran et al.   CLINICAL INFECTIOUS DISEASES

Ceftaroline Fosamil: A Cephalosporin With Activity Against Methicillin-Resistant Staphylococcus Aureus

(2012) Henry Poon et al.   CLINICAL THERAPEUTICS

Spectrum and potency of ceftaroline tested against leading pathogens causing community-acquired respiratory tract infections in Europe (2010)

(2012) David J. Farrell et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Ceftaroline Fosamil in the Treatment of Community-Acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin Structure Infections

(2012) Thomas P. Lodise et al.   DRUGS

Ceftaroline fosamil for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infection

(2012) Anthony M Casapao et al.   EXPERT OPINION ON PHARMACOTHERAPY

Ceftaroline fosamil: a new cephalosporin active against resistant Gram-positive organisms including MRSA

(2012) Mark W Garrison et al.   Expert Review of Anti-Infective Therapy

In vitro activity of ceftaroline and comparator antimicrobials against European and Middle East isolates from complicated skin and skin-structure infections collected in 2008–2009

(2012) Ian Morrissey et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Assessment of the activity of ceftaroline against clinical isolates of penicillin-intermediate and penicillin-resistant Streptococcus pneumoniae with elevated MICs of ceftaroline using an in vitro pharmacodynamic model

(2012) G. G. Zhanel et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Activity of ceftaroline against serotyped Streptococcus pneumoniae isolates from Europe and South Africa associated with community-acquired bacterial pneumonia (2007–08)

(2012) Ian Morrissey et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Characterization of methicillin-resistant Staphylococcus aureus displaying increased MICs of ceftaroline

(2012) R. E. Mendes et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Activity of Ceftaroline and Epidemiologic Trends in Staphylococcus aureus Isolates Collected from 43 Medical Centers in the United States in 2009

(2011) Sandra S. Richter et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Multistep Resistance Development Studies of Ceftaroline in Gram-Positive and -Negative Bacteria

(2011) Catherine Clark et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Ceftaroline versus Ceftriaxone in a Highly Penicillin-Resistant Pneumococcal Pneumonia Rabbit Model Using Simulated Human Dosing

(2011) Delphine Croisier-Bertin et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Efficacy of Human Simulated Exposures of Ceftaroline Administered at 600 Milligrams Every 12 Hours against Phenotypically Diverse Staphylococcus aureus Isolates

(2011) Rebecca A. Keel et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vitro Activity of Ceftaroline against Gram-Positive and Gram-Negative Pathogens Isolated from Patients in Canadian Hospitals in 2009

(2011) James A. Karlowsky et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Evaluation of Ceftaroline Activity versus Daptomycin (DAP) against DAP-Nonsusceptible Methicillin-Resistant Staphylococcus aureus Strains in anIn VitroPharmacokinetic/Pharmacodynamic Model

(2011) Molly Steed et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children

(2011) Catherine Liu et al.   CLINICAL INFECTIOUS DISEASES

Guidelines for the management of adult lower respiratory tract infections - Summary

(2011) M. Woodhead et al.   CLINICAL MICROBIOLOGY AND INFECTION

Integrated safety summary of FOCUS 1 and FOCUS 2 trials: Phase III randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with community-acquired pneumonia

(2011) D. R. Rank et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Ceftaroline fosamil: a new broad-spectrum cephalosporin

(2011) J. B. Laudano   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Ceftaroline pharmacodynamic activity versus community-associated and healthcare-associated methicillin-resistant Staphylococcus aureus, heteroresistant vancomycin-intermediate S. aureus, vancomycin-intermediate S. aureus and vancomycin-resistant S. aureus using an in vitro model

(2011) G. G. Zhanel et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia

(2011) Donald E. Low et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia

(2011) T. M. File et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Comparison of ceftaroline fosamil, daptomycin and tigecycline in an experimental rabbit endocarditis model caused by methicillin-susceptible, methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus

(2011) C. Jacqueline et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Comparative ceftaroline activity tested against pathogens associated with community-acquired pneumonia: results from an international surveillance study

(2011) R. N. Jones et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

General Principles of Antimicrobial Therapy

(2011) Surbhi Leekha et al.   MAYO CLINIC PROCEEDINGS

Affinity of Ceftaroline and Other  -Lactams for Penicillin-Binding Proteins from Staphylococcus aureus and Streptococcus pneumoniae

(2010) K. Kosowska-Shick et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VitroActivity of Ceftaroline against a Broad Spectrum of Recent Clinical Anaerobic Isolates

(2010) David R. Snydman et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vitro Activity of Ceftaroline against 623 Diverse Strains of Anaerobic Bacteria

(2010) D. M. Citron et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Effect of Ceftaroline on Normal Human Intestinal Microflora

(2010) G. Panagiotidis et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vitro Activity of Ceftaroline against Community-Associated Methicillin-Resistant, Vancomycin-Intermediate, Vancomycin-Resistant, and Daptomycin-Nonsusceptible Staphylococcus aureus Isolates

(2010) L. Saravolatz et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Activity of Ceftaroline against Recent Emerging Serotypes of Streptococcus pneumoniae in the United States

(2010) M. R. Jacobs et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Integrated Analysis of CANVAS 1 and 2: Phase 3, Multicenter, Randomized, Double‐Blind Studies to Evaluate the Safety and Efficacy of Ceftaroline versus Vancomycin plus Aztreonam in Complicated Skin and Skin‐Structure Infection

(2010) G. Ralph Corey et al.   CLINICAL INFECTIOUS DISEASES

Integrated Analysis of FOCUS 1 and FOCUS 2: Randomized, Doubled‐Blinded, Multicenter Phase 3 Trials of the Efficacy and Safety of Ceftaroline Fosamil versus Ceftriaxone in Patients with Community‐Acquired Pneumonia

(2010) Thomas M. File et al.   CLINICAL INFECTIOUS DISEASES

Not Community-Associated Methicillin-Resistant Staphylococcus aureus (CA-MRSA)! A Clinician's Guide to Community MRSA - Its Evolving Antimicrobial Resistance and Implications for Therapy

(2010) K. Chua et al.   CLINICAL INFECTIOUS DISEASES

In vitro evaluation of ceftaroline alone and in combination with tobramycin against hospital-acquired meticillin-resistant Staphylococcus aureus (HA-MRSA) isolates

(2010) Céline Vidaillac et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Evolving trends in Streptococcus pneumoniae resistance: implications for therapy of community-acquired bacterial pneumonia

(2010) Ronald N. Jones et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

AmpC induction by ceftaroline

(2010) S. Mushtaq et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections

(2010) M. H. Wilcox et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Efficacy of the new cephalosporin ceftaroline in the treatment of experimental methicillin-resistant Staphylococcus aureus acute osteomyelitis

(2010) C. Jacqueline et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

The problem of complicated skin and skin structure infections: the need for new agents

(2010) R. C. Moellering   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections

(2010) G. R. Corey et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Ceftaroline activity against pathogens associated with complicated skin and skin structure infections: results from an international surveillance study

(2010) R. N. Jones et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Ceftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-Gram-positive activity

(2010) D. Biek et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Binding of ceftaroline to penicillin-binding proteins of Staphylococcus aureus and Streptococcus pneumoniae

(2010) H. Moisan et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Integrated safety summary of CANVAS 1 and 2 trials: Phase III, randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections

(2010) M. L. Corrado   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Community-associated meticillin-resistant Staphylococcus aureus

(2010) Frank R DeLeo et al.   LANCET

Molecular epidemiology of community-associated meticillin-resistant Staphylococcus aureus in Europe

(2010) Jonathan A Otter et al.   LANCET INFECTIOUS DISEASES

Ceftaroline: A New Cephalosporin with Activity Against Resistant Gram-Positive Pathogens

(2010) Molly E Steed et al.   PHARMACOTHERAPY

In Vitro Activity of Ceftaroline Alone and in Combination against Clinical Isolates of Resistant Gram-Negative Pathogens, Including  -Lactamase-Producing Enterobacteriaceae and Pseudomonas aeruginosa

(2009) C. Vidaillac et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vivo Activity of a Novel Anti-Methicillin-Resistant Staphylococcus aureus Cephalosporin, Ceftaroline, against Vancomycin-Susceptible and -Resistant Enterococcus faecalis Strains in a Rabbit Endocarditis Model: a Comparative Study with Linezolid and Vancomycin

(2009) C. Jacqueline et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vitro Activity of Ceftaroline against Methicillin-Resistant Staphylococcus aureus and Heterogeneous Vancomycin-Intermediate S. aureus in a Hollow Fiber Model

(2009) C. Vidaillac et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Clinical impact of antibiotic-resistant Gram-positive pathogens

(2009) H.M. Lode   CLINICAL MICROBIOLOGY AND INFECTION

New treatments for methicillin-resistant Staphylococcus aureus

(2009) Martin E Stryjewski et al.   Current Opinion in Critical Care

Ceftaroline

(2009) George G. Zhanel et al.   DRUGS

Ceftobiprole: a novel cephalosporin with activity against Gram-positive and Gram-negative pathogens, including methicillin-resistant Staphylococcus aureus (MRSA)

(2009) April Barbour et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

In vitro activity of ceftaroline, ceftobiprole and cethromycin against clinical isolates of Streptococcus pneumoniae collected from across Canada between 2003 and 2008

(2009) S. N. Patel et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Limitations of antibiotic options for invasive infections caused by methicillin-resistant Staphylococcus aureus: is combination therapy the answer?

(2009) H. M. Nguyen et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

BTS guidelines for the management of community acquired pneumonia in adults: update 2009

(2009) W S Lim et al.   THORAX

In Vitro Evaluation of the Antimicrobial Activity of Ceftaroline against Cephalosporin-Resistant Isolates of Streptococcus pneumoniae

(2008) L. McGee et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vitro Activity of Ceftaroline against Streptococcus pneumoniae Isolates Exhibiting Resistance to Penicillin, Amoxicillin, and Cefotaxime

(2008) A. Fenoll et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vitro Profiling of Ceftaroline against a Collection of Recent Bacterial Clinical Isolates from across the United States

(2008) Y. Ge et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Broad‐Spectrum Antimicrobials and the Treatment of Serious Bacterial Infections: Getting It Right Up Front

(2008) Marin H. Kollef   CLINICAL INFECTIOUS DISEASES

Guidelines for UK practice for the diagnosis and management of methicillin-resistant Staphylococcus aureus (MRSA) infections presenting in the community

(2008) Dilip Nathwani et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Co-opting the Cell Wall in Fighting Methicillin-ResistantStaphylococcus aureus: Potent Inhibition of PBP 2a by Two Anti-MRSA β-Lactam Antibiotics

(2008) Adriel Villegas-Estrada et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY